AUTHOR CORRECTION

Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study

Yong Yang, Ying Wang, Xin Liu, Xia He, Li-Ling Zhang, Gang Wu, Bao-Lin Qu, Li-Ting Qian, Xiao-Rong Hou, Fu-Quan Zhang, Xue-Ying Qiao, Hua Wang, Gao-Feng Li, Yuan Zhu, Jian-Zhong Cao, Jun-Xin Wu, Tao Wu, Su-Yu Zhu, Mei Shi, Li-Ming Xu , Hang Su, Yu-Qin Song, Jun Zhu, Yu-Jing Zhang, Hui-Qiang Huang, Chen Hu , Shu-Nan Qi and Ye-Xiong Li

© The Author(s), under exclusive licence to Springer Nature Limited 2021

Leukemia (2021) 35:2736–2737; <https://doi.org/10.1038/s41375-021-01371-6>

Correction to: *Leukemia* <https://doi.org/10.1038/s41375-020-01042-y>

Table 3 of the original article was not correct. The corrected version can be found below:

Table 3. SMR and OS after achieving or failure of PFS at selected time points.

PFS time point	No. of Patients	SMR (95% CI)	P ^b	3 years from time point			5 years from time point		
				No. of Patients	Actual 3-y OS ^a % (95% CI)	Expected 3-y OS (%)	No. of Patients	Actual 5-y OS ^a % (95% CI)	Expected 5-y OS (%)
Patients achieved PFS									
All stage (I-IV)									
12 months	1274	3.1 (2.6–3.7)	<0.001	594	88.8 (86.9–90.8)	96.9	195	86.5 (84.1–88.9)	94.4
24 months	1014	1.8 (1.3–2.3)	<0.001	380	94.8 (93.2–96.4)	96.9	100	92.2 (89.6–94.9)	94.3
36 months	793	1.0 (0.6–1.6)	0.953	188	97.0 (95.2–98.8)	97.0	32	93.0 (88.7 –97.5)	94.7
Stage I-II									
12 months	1169	2.7 (2.3–3.3)	<0.001	573	90.2 88.3–92.1)	96.9	190	87.8 (85.4–90.2)	94.4
24 months	950	1.5 (1.1–2.0)	0.009	366	95.5 (94.0–97.1)	96.9	100	92.9 (90.2–95.6)	94.3
36 months	752	1.0 (0.6–1.6)	0.929	183	97.0 (95.2–98.8)	97.0	32	93.0 (88.7–97.6)	94.6
Stage III-IV									
12 months	105	11.4 (7.5–17.4)	<0.001	21	69.7 (59.4–81.7)	97.3	5	69.7 (59.4–81.7)	95.4
24 months	64	9.6 (5.0–18.4)	<0.001	14	83.1 (73.4–94.2)	97.5	–	–	–
36 months	41	2.5 (0.4–18.0)	0.352	5	96.4 (89.8–100)	97.7	–	–	–
Patients with progression									
All stage (I-IV)									
12 months	246	65.8 (56.8–76.2)	<0.001	27	22.9 (17.9–29.5)	96.4	8	17.1 (11.6–25.2)	94.8
24 months	348	71.4 (62.9–81.1)	<0.001	40	24.3 (19.8–30.0)	97.1	14	19.2 (14.3–25.9)	95.8
36 months	388	55.0 (48.7–62.0)	<0.001	41	25.4 (20.9–30.8)	96.4	14	20.3 (15.3–26.8)	93.2
Stage I-II									
12 months	201	62.7 (53.3–73.7)	<0.001	25	23.9 (18.4–31.1)	96.3	7	17.4 (11.5–26.4)	94.6
24 months	289	67.3 (58.5–77.2)	<0.001	37	25.8 (20.9–32.0)	97.0	13	20.1 (14.7–27.4)	95.6
36 months	325	50.4 (44.2–57.6)	<0.001	38	26.9 (22.1–32.9)	96.3	13	21.2 (15.9–28.4)	92.8
Stage III-IV									
12 months	45	85.9 (60.4–122.2)	<0.001	2	14.5 (5.6–37.4)	97.4	–	–	–
24 months	59	103.6 (76.0–141.3)	<0.001	3	13.7 (5.9–31.8)	97.9	–	–	–
36 months	63	103.4 (76.4–140.0)	<0.001	3	13.8 (6.0–31.9)	97.9	–	–	–

SMR standardized mortality ratio, OS overall survival, PFS progression-free survival.

^aActual 3- or 5-year OS was defined as subsequent OS of patients who achieved or failed to achieve PFS at 12, 24 or 36 months after initial treatment based on patients with ENKTCL vs. expected 3- or 5-year OS based on age-, sex- and country-matched general population data.^bCompared with the age- and sex-matched general Chinese population.